Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2003-09-19
2010-06-22
Robert, Mondesi (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S093100, C424S085100, C424S231100, C435S325000, C435S455000, C514S04400A
Reexamination Certificate
active
07740871
ABSTRACT:
A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficient to induce or stimulate an immune response to the viral-associated disease or cancer, or (iii) an immunomodulator and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficient to induce or stimulate an immune response to the viral associated disease or cancer.
REFERENCES:
patent: 6464973 (2002-10-01), Levitsky et al.
patent: WO 99/38954 (1999-08-01), None
Morishima et al. J. Exp. Immunol. 1999, vol. 115, pp. 385-392.
Draneff et al. 2002, vol. 188, pp. 147-154.
Nedospasov et al. Molecular Biology 2007, vol. 41, No. 2, pp. 316-328.
Borrello et al. Human Gen Therapy, 1999, vol. 10, pp. 1983-1991.
Lee et al. J. Immunol. 1997, vol. 158, pp. 3325-3334.
Nawrocki et al. Cancer Treatment Reviews, vol. 25, No. 1, Feb. 1999, pp. 29-46.
Asada et al., “Significant Antitumor Effects Obtained by Autologous Tumor Cell Vaccine Engineered to Secrete Interleukin (IL)-12 and IL-18 by Means of the EBV/Lipoplex,”Molecular Therapy, vol. 5(5), 609-616 (2002).
Khanna et al., “Immune Regulation in Epstein-Barr Virus-Associated Diseases,”Microbiological Reviews, vol. 59(3), 387-405 (1995).
Ambinder Richard F.
Borrello Ivan M.
Levitsky Hyam I.
Yang Yiping
Barnes & Thornburg LLP
Johns Hopkins University School of Medicine
Li Bao Qun
Robert Mondesi
LandOfFree
Cancer immunotherapy with a viral antigen-defined,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer immunotherapy with a viral antigen-defined,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer immunotherapy with a viral antigen-defined,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4235996